Should I buy Fortrea (FTRE) stock or is it too late?

Fortrea · Health Care · price $21
Logo FortreaSee the full Fortrea (FTRE) profile
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS — 59% of its targets hit on this sector (76 calls tested). It aims for $22 (+5.2 %), call made on October 1, 2026, maturing on October 1, 2027 (13 d ago).

The 1 reliable analyst $22+5.2 %
The 6 other firms $23+9.9 %
How to read it: the 1 reliable firms are not filtered by optimism — 1 aim above the price, 0 below, hence their $22 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Fortrea

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.
Firm% rightGain vs sectorCallsAims for
Baird33 %+3.2 %6$16 -24%
Barclays0 %-104.8 %6$23 +10%
B of A Securities100 %+63.7 %5—
In short — Should you invest in Fortrea? Is it too late, still worth it? Analysts are fairly positive (71% buy, median target $23, i.e. +10%). But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

  • 71% of analysts rate it a buy (Buy consensus, 7 ratings) — a sign of market conviction.
  • Median price target $23, i.e. +10% from the current price ($21).

⚠️ Reasons to hesitate

  • Even the most reliable firm on FTRE, Baird (33% hit rate, 6 scored calls), only targets $16 (call made on February 27, 2026, maturing on February 27, 2027) (-24%) in its most recent call. The stock may already have run past its target.
  • The consensus is not unanimous: of 7 ratings, 2 are neutral.
  • A 12-month target is not a guaranteed path: the price can fall in the meantime.
  • No dividend: your return depends only on price appreciation.

The analyst consensus on FTRE

Median target $23 (+10%) · 7 ratings · Buy consensus

Strong Buy00%
Buy571%
Hold229%
Sell00%
Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Fortrea now?

We won't decide for you. The facts: 71% of analysts rate it a buy, median target $23 (+10%), and Baird (most reliable on FTRE, 33%) targets $16. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Fortrea?

Not according to analysts: the median target ($23) is still +10% above the current price ($21) (most reliable on FTRE: Baird, 33%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Fortrea still worth investing in?

It depends on the gap between the price ($21) and its estimated value: analysts target $23 on median (+10%), with 71% buys (most reliable on FTRE: Baird, 33%). Cross-check with their real reliability on FTRE and the cautions above. Information, not advice.

What's the main risk in buying FTRE?

Even the most reliable firm on FTRE, Baird (33% hit rate, 6 scored calls), only targets $16 (call made on February 27, 2026, maturing on February 27, 2027) (-24%) in its most recent call. The stock may already have run past its target.

→ Go deeper: the full Fortrea profile (consensus, analyst reliability, price target, performance).

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)